Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis [Phase 3]

View source ↗

Summary

Phase 3 trial update on lebekizumab for moderate-to-severe atopic hand and foot dermatitis has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Hand and Foot Dermatitis

Drugs mentioned

• Lebrikizumab (lebrikizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Atopic Hand and Foot Dermatitis | Phase 3 | Status: COMPLETED